bioAffinity Technologies, Inc. (BIAF) AI Stock Analysis

• Market Cap: $7.14M
• Dividend Yield: N/A
• Average Volume (3M): 4.43M
• Price to Earnings (P/E): ―
• Beta (1Y): -2.45
• Revenue Growth: 78.40%
• EPS Growth: 22.41%
• Country: US
• Employees: 57
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.16
• Shares Outstanding: 27,249,462
• 10 Day Avg. Volume: 11,891,175
• 30 Day Avg. Volume: 4,432,883
• PEG Ratio: -0.08
• Price to Book (P/B): 2.96
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.07
• Enterprise Value/Market Cap: 1.12
• Enterprise Value/Revenue: 0.23
• Enterprise Value/Gross Profit: 2.65
• Enterprise Value/Ebitda: -0.24
• 1Y Price Target: $6.00
• Price Target Upside: 2207.69% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 51 Neutral
• Price Target: $0.50 ▲( 92.31% Upside)

BIAF's overall stock score of 51 reflects its financial instability due to high leverage and negative profit margins, despite some potential for revenue growth. Technical analysis indicates weak momentum, and the negative P/E ratio suggests valuation challenges. The lack of earnings call data and corporate events means these factors do not impact the score.

Positive Factors

Market Expansion

CyPath Lung was added to the US Federal Supply Schedule, allowing VA and Military Health System physicians to order the test.

Product Adoption

The number of physician offices offering the CyPath Lung test increased significantly, indicating growing adoption of the diagnostic test.

Revenue Growth

Even without current FDA approval, BIAF’s commercialization strategy as an LDT is driving significant testing volume and revenue growth.

Negative Factors

Capital Needs

The company needs to raise additional capital immediately, which could lead to share dilution for current shareholders.

Profitability Concerns

Despite the novel diagnostic technology and market potential, the company's inability to operate profitably without raising additional funds is concerning.

Revenue Guidance

The company introduced 2025 revenue guidance significantly below prior estimates, leading to a downgrade of the stock to Hold.

bioAffinity Technologies, Inc. Business Overview & Revenue Model

Company Description

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

How the Company Makes Money

bioAffinity Technologies makes money through the commercialization of its diagnostic tests, including CyPath Lung, which is marketed to healthcare providers and laboratories. The company generates revenue by selling these tests to medical institutions, which use them for early cancer detection. In addition to direct sales, bioAffinity Technologies may engage in strategic partnerships or licensing agreements with other healthcare companies to expand the reach and application of its technologies, potentially leading to additional revenue streams.

bioAffinity Technologies, Inc. Financial Statement Overview

Summary

bioAffinity Technologies, Inc. has demonstrated revenue growth, which is a positive sign for future potential. However, the company continues to face significant profitability challenges, with persistent net losses and negative cash flows. The balance sheet shows high leverage, which could pose risks if not managed effectively. Overall, while there are promising revenue trends, the financial health remains fragile with ongoing operational and financial hurdles.

Income Statement

bioAffinity Technologies, Inc. has shown notable revenue growth from 2022 to 2023, with a substantial increase in total revenue from $4,803 to $2,532,499. However, the company is still experiencing significant net losses, with a net profit margin of -96.5% in 2023. The EBIT margin has also been negative, indicating operational challenges. Despite the revenue growth, the profitability metrics remain concerning.

Balance Sheet

The company has a high debt-to-equity ratio, reflecting significant leverage, although it has improved from previous years. The equity ratio remains low, indicating a reliance on debt financing. The return on equity is negative due to persistent net losses. Overall, the balance sheet shows signs of financial stress despite some improvement in equity levels.

Cash Flow

Operating cash flow remains negative, which is a concern, but there has been some reduction in negative free cash flow. The company’s financing activities have provided cash inflows, suggesting reliance on external funding. The free cash flow to net income ratio is improving but still negative, reflecting ongoing cash flow challenges.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
8.81M	9.36M	2.53M	4.80K	0.00	0.00
	Gross Profit
3.03M	3.38M	791.62K	4.34K	-4.82K	-22.24K
	EBIT
-9.64M	-8.95M	-7.97M	-4.01M	-2.21M	-2.60M
	EBITDA
-9.02M	-8.33M	-7.63M	-5.61M	-2.20M	-6.86M
	Net Income Common Stockholders
-9.74M	-9.04M	-7.94M	-8.15M	-6.33M	-7.27M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.82M	1.11M	2.82M	11.41M	1.36M	83.11K
	Total Assets
8.22M	6.51M	8.22M	12.18M	1.45M	145.60K
	Total Debt
1.58M	1.50M	1.58M	251.75K	11.36M	10.01M
	Net Debt
-1.24M	395.90K	-1.24M	-11.16M	10.00M	9.92M
	Total Liabilities
3.37M	3.91M	3.37M	1.14M	17.24M	15.22M
	Stockholders Equity
4.86M	2.60M	4.86M	11.04M	-15.79M	-15.07M
Cash Flow		Free Cash Flow
-6.65M	-7.34M	-6.06M	-4.29M	-2.05M	-2.21M
	Operating Cash Flow
-6.56M	-7.26M	-6.04M	-4.07M	-2.05M	-2.21M
	Investing Cash Flow
-88.48K	-79.08K	-2.21M	-219.99K	0.00	-2.89K
	Financing Cash Flow
4.64M	5.63M	-344.98K	14.34M	3.33M	1.72M

bioAffinity Technologies, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIAF, the sentiment is Negative. The current price of 0.26 is below the 20-day moving average (MA) of 0.30, below the 50-day MA of 0.40, and below the 200-day MA of 1.03, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 41.33 is Neutral, neither overbought nor oversold. The STOCH value of 65.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIAF.

bioAffinity Technologies, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRPO	66 Neutral	$14.63M	―	-25.29%	―	26.67%	44.02%
Sector *	53 Neutral	$5.14B	3.03	-44.09%	2.83%	16.75%	-0.06%
BIAF	51 Neutral	$7.14M	―	-290.85%	―	78.40%	22.41%
INBS	49 Neutral	$9.74M	―	-126.34%	―	3.87%	35.37%
BNGO	45 Neutral	$12.51M	―	-127.82%	―	-24.04%	84.11%
MYNZ	42 Neutral	$8.01M	―	-809.29%	―	―	―
TRIB	35 Underperform	$12.88M	―	77.20%	―	-3.76%	39.52%

bioAffinity Technologies, Inc. Corporate Events

bioAffinity Technologies Sets 2025 Annual Meeting Date

bioAffinity Technologies, Inc. has announced plans for its 2025 Annual Meeting of Stockholders, which will take place on July 25, 2025. The company has set the record date for determining stockholders entitled to vote at the meeting as May 29, 2025. Due to the meeting being scheduled more than 30 days after the previous year’s meeting, revised deadlines for stockholder proposals have been provided. Proposals under Rule 14a-8 must be submitted by May 26, 2025, while notices for director nominations must comply with Rule 14a-19 by May 29, 2025.

The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

bioAffinity Technologies Completes $3.2M Public Offering

On May 7, 2025, bioAffinity Technologies, Inc. completed a public offering of common stock and warrants, raising approximately $3.2 million in gross proceeds. The company plans to use the funds for working capital and general corporate purposes. The offering included agreements that restrict the issuance of additional shares for a specified period, which may impact the company’s market activities and shareholder interests.

bioAffinity Technologies Board Member Announces Departure

On April 12, 2025, Stuart Diamond, a board member of bioAffinity Technologies, Inc., announced he will not seek re-election at the company’s 2025 annual stockholders’ meeting. His decision was not due to any disagreements with the company’s operations or policies.